KVK Tech: The Computer Controls Behind the Medicine

In the KVK Tech adulterated drugs settlement, KVK Tech agreed to pay $2 million to resolve False Claims Act allegations tied to manufacturing without required controls, which KVK Tech admitted in its criminal case were computer-system controls. KVK Tech is a generic drug manufacturer. The Department of Justice announced the resolution on March 6, 2024.

The civil allegations put manufacturing controls at the center of the case. For someone in quality assurance or manufacturing systems, the concern reaches the information behind production and quality decisions. The medicine leaves the plant, but the people working inside it know how the business decided it was ready to leave.

Computer Controls Behind the Finished Drug

Under its deferred prosecution agreement in the criminal case, KVK Tech admitted making prescription drugs without the controls that current good manufacturing practice regulations require over computer and related systems. Under federal law, drugs made without those controls are deemed adulterated. The civil settlement covered drugs KVK Tech made and sold between February 27 and April 16, 2019, and the government alleged that those sales resulted in false claims to TRICARE, the Federal Employees Health Benefits Program, the Department of Veterans Affairs and the Department of Labor’s workers’ compensation program. For an insider, the practical importance is the reliability of the information supporting production and quality decisions.

We examine manufacturing systems alongside the production they support. What information supported a quality decision, how did the system control that information, and what happened when a concern arose? An employee who works with the system can explain what a control does in the actual operation, which work depends on it and who responds when it fails.

That technical knowledge makes a broad allegation understandable. Someone familiar with the laboratory can explain the results used in a quality review. A colleague responsible for release decisions can explain how those results reached the people deciding whether the product should ship. We bring those accounts together around the affected production and the decisions made about it.

The distinction matters to the people buying and taking the medicine. They rely on the manufacturer’s quality work without seeing the decisions behind it. When manufacturing failures lead to false claims, taxpayers pay for drugs that should not have reached them on those terms.

From Manufacturing Controls to Government Payment

The False Claims Act reaches companies that knowingly cause false claims, including where another business submits the bill. That is why a concern originating inside a plant can matter beyond the plant’s own sales invoices.

The drug’s route through the supply chain and the route of payment need separate attention. The physical chain runs from manufacturer to wholesaler to dispenser. Financial arrangements connect those businesses differently. A manufacturer’s sale to a wholesaler and a pharmacy’s claim for reimbursement describe different transactions involving the medicine.

For pharmaceutical fraud cases involving manufacturing, we examine the connection between the product, the quality information behind it and the government payment. A manufacturing employee brings knowledge of the production side. We work with that employee and pharmaceutical whistleblower lawyers to connect the plant’s decisions to the claims those decisions caused.

Gilead’s Alleged Use of an Unapproved Ingredient Source

A separate whistleblower complaint against Gilead Sciences illustrates another manufacturing decision that insiders can identify. The whistleblowers alleged that active pharmaceutical ingredient from Gilead Alberta went into clinical studies and commercial lots before Gilead even applied for FDA approval of the site. The alleged sequence was simple: use the source, make the product, seek approval later.

A purchasing employee may know the supplier decision, while someone working with batch records may understand where that ingredient went. In examining a concern like this, we compare the source used in production with the source authorized for that production. The useful connection is between the ingredient actually used and the batches made from it.

The 2021 Proceedings paper Risks of Corruption in the Healthcare and Pharmaceutical Sector and the Impact of a Pandemic identifies weak supervision as an opening for pharmaceutical companies and regulators to pursue unfair practices to accelerate product approval. Its analysis puts the incentive at the approval stage, before the medicine reaches the buyer.

The Gilead allegation shows why the order of events matters. Approval history and production history tell different parts of that story. An insider who knows when a source entered commercial production can help us understand what the company was doing while approval was still ahead of it.

When the Quality Record Disappears

A separate case involving GlaxoSmithKline’s Cidra plant ended in a far larger civil settlement than KVK’s. The government announced a $600 million civil settlement in 2010 over allegations that the company caused claims for adulterated drugs made there. The different amounts sit beside a common concern: what the manufacturer knew about the medicine it continued to supply.

The whistleblower’s complaint described a practice that would leave people discussing a problem while removing the record of what they had discussed:

The report was allegedly discarded after the responsible personnel had heard about the problems. What they knew and what remained on paper could then diverge.

Elsewhere, the complaint described drums reused for different types or strengths of tablets and uncoated tablets of different types becoming mixed together. Yet, the whistleblower alleged, Cidra told the FDA that mix-ups were extremely unlikely to have happened at the site and must have occurred outside the company’s control. The people inside the plant were describing one thing. The account sent outside it said another.

The complaint also alleged that the plant continued making and releasing products while process investigations remained overdue. The quality records concerned decisions about medicine that was still leaving the plant. That is the useful parallel for a reader concerned about manufacturing controls: how the business handles information about its own production.

What Evidence Is Needed to Prove Fraud?

We connect the affected production, the company’s decisions and the claims for government payment. We work with pharmaceutical whistleblowers to make those connections around what they know from their work.

On a computer-control concern, we examine the system’s role in manufacturing and quality work, the control at issue and the decisions that depended on it. On an ingredient-source concern, we examine the relationship between supplier information, approval history and the batches that used the ingredient.

An insider’s account can also explain why a record matters. A batch identifier may connect production information that otherwise looks unrelated. A quality finding may explain a later decision to release a product. We assess those connections with you and bring the manufacturing account together with the payment evidence.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know the Production Behind the Paperwork

If your work gives you a view of missing manufacturing controls or quality findings that never reach the people relying on them, speak with our whistleblower experts about the decisions behind the medicine. We build your strongest pharmaceutical whistleblower case with you, bring in pharmaceutical whistleblower lawyers who understand manufacturing and government-payment claims, and remain your partners through the case.